Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda has acquired exclusive US, Canadian and Japanese rights for the use of Flupirtine to treat fibromyalgia from Adeona Pharmaceuticals.
Subscribe to our email newsletter
As part of the agreement, Meda is expected to take over full responsibility for development and commercialisation of the compound. Flupirtine is currently in Phase II development for the patented indication fibromyalgia.
Reportedly, there are presently three products namely Lyrica, Cymbalta and Savella approved for this indication in the US. Meda estimates the US market for fibromyalgia to be near $1bn at launch of Flupirtine.
Meda said that Flupirtine’s neuroprotective properties can be leveraged to treat new indications outside of pain and fibromyalgia, resulting in robust product lifecycle opportunities.
Under the agreement with Adeona, Meda is expected to make an up-front payment of $2,5m. In addition, Meda is expected to make a milestone payments of $5m upon the FDA’s acceptance of the new drug application (NDA), and $10m upon NDA approval by the FDA. Meda is also expected to pay single digit royalties to Adeona.
Anders Lonner, CEO of Meda, said: “Flupirtine has the potential to have better efficacy and safety than current treatments. Additionally, Flupirtine has displayed tolerability during all the years it has been used for the treatment of acute and chronic pain.”